Radiolabeling with Tb-161 and Lu-177: defining the impact of metal impurities

Research output: Contribution to report/book/conference proceedingsIn-proceedings paperpeer-review

Standard

Radiolabeling with Tb-161 and Lu-177: defining the impact of metal impurities. / Ooms, Maarten; Burgoyne, Andrew; Ponsard, Bernard; Elema, Dennis; Cardinaels, Thomas; Van de Voorde, Michiel.

European Journal of Nuclear Medicine and Molecular Imaging. Vol. 47 Supplement 1. ed. 2020. p. 677 EP-340 (European Journal of Nuclear Medicine and Molecular Imaging ).

Research output: Contribution to report/book/conference proceedingsIn-proceedings paperpeer-review

Harvard

Ooms, M, Burgoyne, A, Ponsard, B, Elema, D, Cardinaels, T & Van de Voorde, M 2020, Radiolabeling with Tb-161 and Lu-177: defining the impact of metal impurities. in European Journal of Nuclear Medicine and Molecular Imaging. Supplement 1 edn, vol. 47, EP-340, European Journal of Nuclear Medicine and Molecular Imaging , pp. 677, 2020 - EANM, 2020-10-22. https://doi.org/10.1007/s00259-020-04988-4

APA

Ooms, M., Burgoyne, A., Ponsard, B., Elema, D., Cardinaels, T., & Van de Voorde, M. (2020). Radiolabeling with Tb-161 and Lu-177: defining the impact of metal impurities. In European Journal of Nuclear Medicine and Molecular Imaging (Supplement 1 ed., Vol. 47, pp. 677). [EP-340] (European Journal of Nuclear Medicine and Molecular Imaging ). https://doi.org/10.1007/s00259-020-04988-4

Vancouver

Ooms M, Burgoyne A, Ponsard B, Elema D, Cardinaels T, Van de Voorde M. Radiolabeling with Tb-161 and Lu-177: defining the impact of metal impurities. In European Journal of Nuclear Medicine and Molecular Imaging. Supplement 1 ed. Vol. 47. 2020. p. 677. EP-340. (European Journal of Nuclear Medicine and Molecular Imaging ). https://doi.org/10.1007/s00259-020-04988-4

Author

Ooms, Maarten ; Burgoyne, Andrew ; Ponsard, Bernard ; Elema, Dennis ; Cardinaels, Thomas ; Van de Voorde, Michiel. / Radiolabeling with Tb-161 and Lu-177: defining the impact of metal impurities. European Journal of Nuclear Medicine and Molecular Imaging. Vol. 47 Supplement 1. ed. 2020. pp. 677 (European Journal of Nuclear Medicine and Molecular Imaging ).

Bibtex - Download

@inproceedings{f7247e9667dc46a182d00062088c0486,
title = "Radiolabeling with Tb-161 and Lu-177: defining the impact of metal impurities",
abstract = "161Tb and 177Lu prove to be highly valuable in the fight against cancer as they can be deployed in targeted radionuclide therapy. 177Lu-based radiopharmaceuticals are currently being widely explored, whereas interest in 161Tb as therapeutic radioisotope is growing rapidly because of its very comparable decay properties. Moreover, 161Tb is expected to have an improved therapeutic effect because of its simultaneous emission of conversion and Auger electron emission. SCK CEN recently developed in-house production methods for 161Tb [1] and 177Lu with high radionuclidic purity. However, also metal impurities are of major concern since they have the potential to compete with the radionuclide during radiolabeling. In this study we aimed to identify and quantify the effect of metal impurities on the radiolabeling of 161Tb and 177Lu.",
keywords = "Tb-161, Lu-177, Radionuclide therapy, Radiopharmaceuticals",
author = "Maarten Ooms and Andrew Burgoyne and Bernard Ponsard and Dennis Elema and Thomas Cardinaels and {Van de Voorde}, Michiel",
note = "Score=3; 2020 - EANM : European Association of Nuclear Medicine ; Conference date: 22-10-2020 Through 30-10-2020",
year = "2020",
month = oct,
day = "30",
doi = "10.1007/s00259-020-04988-4",
language = "English",
volume = "47",
series = "European Journal of Nuclear Medicine and Molecular Imaging ",
publisher = "Springer",
pages = "677",
booktitle = "European Journal of Nuclear Medicine and Molecular Imaging",
edition = "Supplement 1",
url = "https://eanm20.eanm.org/",

}

RIS - Download

TY - GEN

T1 - Radiolabeling with Tb-161 and Lu-177: defining the impact of metal impurities

AU - Ooms, Maarten

AU - Burgoyne, Andrew

AU - Ponsard, Bernard

AU - Elema, Dennis

AU - Cardinaels, Thomas

AU - Van de Voorde, Michiel

N1 - Score=3

PY - 2020/10/30

Y1 - 2020/10/30

N2 - 161Tb and 177Lu prove to be highly valuable in the fight against cancer as they can be deployed in targeted radionuclide therapy. 177Lu-based radiopharmaceuticals are currently being widely explored, whereas interest in 161Tb as therapeutic radioisotope is growing rapidly because of its very comparable decay properties. Moreover, 161Tb is expected to have an improved therapeutic effect because of its simultaneous emission of conversion and Auger electron emission. SCK CEN recently developed in-house production methods for 161Tb [1] and 177Lu with high radionuclidic purity. However, also metal impurities are of major concern since they have the potential to compete with the radionuclide during radiolabeling. In this study we aimed to identify and quantify the effect of metal impurities on the radiolabeling of 161Tb and 177Lu.

AB - 161Tb and 177Lu prove to be highly valuable in the fight against cancer as they can be deployed in targeted radionuclide therapy. 177Lu-based radiopharmaceuticals are currently being widely explored, whereas interest in 161Tb as therapeutic radioisotope is growing rapidly because of its very comparable decay properties. Moreover, 161Tb is expected to have an improved therapeutic effect because of its simultaneous emission of conversion and Auger electron emission. SCK CEN recently developed in-house production methods for 161Tb [1] and 177Lu with high radionuclidic purity. However, also metal impurities are of major concern since they have the potential to compete with the radionuclide during radiolabeling. In this study we aimed to identify and quantify the effect of metal impurities on the radiolabeling of 161Tb and 177Lu.

KW - Tb-161

KW - Lu-177

KW - Radionuclide therapy

KW - Radiopharmaceuticals

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/42349918

U2 - 10.1007/s00259-020-04988-4

DO - 10.1007/s00259-020-04988-4

M3 - In-proceedings paper

VL - 47

T3 - European Journal of Nuclear Medicine and Molecular Imaging

SP - 677

BT - European Journal of Nuclear Medicine and Molecular Imaging

T2 - 2020 - EANM

Y2 - 22 October 2020 through 30 October 2020

ER -

ID: 7070273